Angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Protease inhibitors such as tipranavir or ritonavir may decrease the serum concentration of abacavir through induction of glucuronidation. Abacavir is metabolized by both alcohol dehydrogenase and glucuronidation. Ethanol may result in increased levels of abacavir through the inhibition of alcohol dehydrogenase. Abacavir is metabolized by both alcohol dehydrogenase and glucuronidation. Methadone may diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone. Orlistat may decrease the serum concentration of antiretroviral drugs. The mechanism of this interaction is not fully established but it is suspected that it is due to the decreased absorption of abacavir by orlistat. Cabozantinib: Drugs from the MRP2 inhibitor (Multidrug resistance-associated protein 2 inhibitors) family such as abacavir could increase the serum concentration of Cabozantinib.
In 2009, Valve hired IceFrog, the developer of Defense of the Ancients, a Warcraft III mod. IceFrog led the development of a sequel not associated with the Warcraft elements, Dota 2, released in 2013. Alongside Dota 2 in 2011, Valve started the International, an annual esports tournament for Dota 2 with a prize pool supported by Valve and funds from microtransactions from battle passes purchased by players. Valve released Portal 2 in April 2011. As with the original Portal, Valve employed a Digipen student team to help develop it; the team behind Tag: The Power of Paint implemented the new gel gameplay. In April 2010, Valve launched Steam for Mac OS X along with ports of several of its games including the Half-Life series. The Screen Digest analyst Ed Barton estimated Valve's 2010 revenue to be in the "high hundreds of millions of dollars". As of 2011, Valve had an estimated worth of $2 to 4 billion and employed 250 people; according to Newell, this made it more profitable per employee than Google or Apple. Most of Valve's revenue came from Steam, which controlled 50 to 70% of the market for downloaded PC games in 2011. By 2011, Valve had replaced episodic development with a platform-oriented approach, whereby games such as Left 4 Dead 2 and Team Fortress 2 were continually updated through Steam updates. In June 2012, Valve hired the economist Yanis Varoufakis to study the online economies of their games. That December, Valve acquired Star Filled Studios, a two-person studio, to open a San Francisco office.
=== Human rights impact === Extraction of raw materials for lithium-ion batteries may present dangers to local people, especially land-based indigenous populations. Cobalt sourced from the Democratic Republic of the Congo is often mined by workers using hand tools with few safety precautions, resulting in frequent injuries and deaths. Pollution from these mines has exposed people to toxic chemicals that health officials believe to cause birth defects and breathing difficulties. Human rights activists have alleged, and investigative journalism reported confirmation, that child labor is used in these mines. A study of relationships between lithium extraction companies and indigenous peoples in Argentina indicated that the state may not have protected indigenous peoples' right to free prior and informed consent, and that extraction companies generally controlled community access to information and set the terms for discussion of the projects and benefit sharing. Development of the Thacker Pass lithium mine in Nevada, USA has been met with protests and lawsuits from several indigenous tribes who have said they were not provided free prior and informed consent and that the project threatens cultural and sacred sites. Links between resource extraction and missing and murdered indigenous women have also prompted local communities to express concerns that the project will create risks to indigenous women. Protestors have been occupying the site of the proposed mine since January, 2021.
=== Files === Copying files: Making copies of files is the simplest and most common way to perform a backup. A means to perform this basic function is included in all backup software and all operating systems. Partial file copying: A backup may include only the blocks or bytes within a file that have changed in a given period of time. This can substantially reduce needed storage space, but requires higher sophistication to reconstruct files in a restore situation. Some implementations require integration with the source file system. Deleted files: To prevent the unintentional restoration of files that have been intentionally deleted, a record of the deletion must be kept. Versioning of files: Most backup applications, other than those that do only full only/System imaging, also back up files that have been modified since the last backup. "That way, you can retrieve many different versions of a given file, and if you delete it on your hard disk, you can still find it in your [information repository] archive."
Endogenous Originating from within an organism, tissue, or cell. In neuroscience, it typically refers to naturally occurring neurotransmitters or signaling molecules. Endorphins Endogenous opioid peptides that bind to opioid receptors and act as natural painkillers and mood enhancers. Engram A theoretical physical trace or biological substrate of memory in the brain. The term is used in memory research to describe the neural changes underlying a specific memory. Enteric nervous system A subdivision of the autonomic nervous system that governs the function of the gastrointestinal system. Sometimes called the "second brain." Epinephrine A hormone and neurotransmitter (also known as adrenaline) involved in the body’s fight-or-flight response. Produced in the adrenal medulla. EPSP (Excitatory Postsynaptic Potential) A depolarizing event in a postsynaptic neuron caused by the influx of positive ions, making the neuron more likely to fire an action potential. Equilibrium potential The membrane potential at which there is no net flow of a particular ion across the cell membrane. It can be calculated using the Nernst equation. Estrogen A steroid hormone that, in addition to reproductive functions, affects brain structure, cognition, and neuroprotection, particularly in areas such as the hippocampus. Evoked potential A measured electrical response of the nervous system to a specific sensory, motor, or cognitive stimulus, commonly recorded with EEG. Excitability The ability of a neuron or muscle cell to respond to a stimulus and generate an action potential.
Sources: en.wikipedia.org
The Buran could be fitted with four Saturn AL-31 turbofan engines and a fuel tank in its payload bay, allowing it to make its own atmospheric test flights, which began in November 1985. Also unlike the US Shuttle, it could be flown pilotlessly and landed automatically. Energia-Buran made only one orbital test flight in November 1988, but US counterintelligence baited the Soviets with disinformation about the heat shield design, and it was not reusable for repeated flight. Buran was the largest and most expensive Soviet program in the history of the Space Race, and was effectively canceled by the collapse of the Soviet Union in 1991, due to lack of funding. The Energia was also canceled at the same time, after only two flights.
As of May 2021, Pakistan operates six licensed commercial nuclear power plants. The Pakistan Atomic Energy Commission (PAEC) oversees these plants, while the Pakistan Nuclear Regulatory Authority ensures their safe operation. These plants contribute approximately 5.8% to Pakistan's electricity supply, while fossil fuels (crude oil and natural gas) provide 64.2%, hydroelectric power provides 29.9%, and coal contributes 0.1%. The KANUPP-I, Pakistan's first commercial nuclear power plant, was supplied by Canada in 1971. Sino-Pakistani nuclear cooperation began in the 1980s, leading to the establishment of CHASNUPP-I. In 2005, both countries proposed a joint energy security plan, aiming for a generation capacity exceeding 160,000 MWe by 2030. Pakistan's Nuclear Energy Vision 2050 targets a capacity of 40,000 MWe, with 8,900 MWe expected by 2030. In June 2008, the nuclear complex at Chashma in Punjab Province expanded with the installation of Chashma-III and Chashma–IV reactors, each with 325–340 MWe, costing ₨129 billion, with ₨80 billion from international sources, mainly China. Another agreement for China's assistance was signed in October 2008, seen as a response to the US–India agreement. The project's cost was then US$1.7 billion, with a foreign loan of US$1.07 billion. In 2013, Pakistan established a second nuclear complex in Karachi with plans for additional reactors, similar to Chashma. Electrical energy in Pakistan is generated by various corporations and distributed evenly among the four provinces by the National Electric Power Regulatory Authority (NEPRA).
In Australia, as of 2013 the drug was authorized for prescribing for severe cases of insomnia but was restricted as a Schedule 8 medicine. In France, as of 2016 flunitrazepam was not marketed. In Germany, as of 2016 flunitrazepam is an Anlage III Betäubungsmittel (controlled substance which is allowed to be marketed and prescribed by physicians under specific provisions) and is available on a special narcotic drug prescription as the Rohypnol 1 mg film-coated tablets and several generic preparations (November 2016). In Ireland, flunitrazepam is a Schedule 3 controlled substance with strict restrictions. In Japan, flunitrazepam is marketed by Japanese pharmaceutical company Chugai under the trade name Rohypnol and is indicated for the treatment of insomnia as well as used for preanesthetic medication. In Mexico, Rohypnol is legally available. In Norway, on January 1, 2003, flunitrazepam was moved up one level in the schedule of controlled drugs and, on August 1, 2004, the manufacturer Roche removed Rohypnol from the market there altogether. In South Africa, Rohypnol is classified as a Schedule 6 drug. It is available by prescription only, and restricted to 1 mg doses.
== Chemistry == Teicoplanin (TARGOCID, marketed by Sanofi Aventis Ltd) is actually a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1 — a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety — β-D-glucosamine — and differ only by the length and conformation of a side-chain attached to it. Teicoplanin A2-4 and RS-3 have chiral side chains while all other side chains are achiral. Teicoplanin A3 lacks both the side chains as well as the β-D-glucosamine moiety. The structures of the teicoplanin core and the side-chains that characterize the five major as well as four minor teicoplanin compounds are shown below.
Abdominal fullness related to an enlarged spleen (splenomegaly). Enlargement of both the liver and spleen Splenomegaly due to extramedullary hematopoiesis (hematopoiesis occurring outside of the bone marrow) Bone pain Bruising and easy bleeding due to inadequate numbers of platelets Increased risk of thrombosis Cachexia (loss of appetite, weight loss, and fatigue) Fatigue Fevers Chills Weight loss Gout and high uric acid levels Increased susceptibility to infection, such as pneumonia Pallor and shortness of breath due to anemia Leukoerythroblastic smear (tear-drop RBCs, nucleated RBCs, and immature granulocytes) In rarer cases, a raised red blood cell volume Cutaneous myelofibrosis is a rare skin condition characterized by dermal and subcutaneous nodules.
Sources: en.wikipedia.org
=== Other indications === Sertraline is approved for the treatment of post-traumatic stress disorder (PTSD). The UK's National Institute for Clinical Excellence recommends it for patients who prefer drug treatment to a psychological one. Other guidelines also suggest sertraline as a first-line option for pharmacological therapy. When necessary, long-term pharmacotherapy can be beneficial. There are both negative and positive clinical trial results for sertraline, which may be explained by the types of psychological traumas, symptoms, and comorbidities included in the various studies. Positive results were obtained in trials that included predominantly women (75%) with a majority (60%) having physical or sexual assault as the traumatic event. Somewhat contrary to the above suggestions, a meta-analysis of sertraline clinical trials for PTSD found it to be statistically superior to placebo in the reduction of PTSD symptoms but the effect size was small. Another meta-analysis relegated sertraline to the second line, proposing trauma focused psychotherapy as a first-line intervention. The authors noted that Pfizer had declined to submit the results of a negative trial for inclusion in the meta-analysis, making the results unreliable. Sertraline, when taken daily, can be useful for the treatment of premature ejaculation. A disadvantage of sertraline is that it requires continuous daily treatment to delay ejaculation significantly.
MDDMA, or MDDM, also known as 3,4-methylenedioxy-N,N-dimethylamphetamine or as N,N-dimethyl-MDA or N-methyl-MDMA, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families. It is the N,N-dimethyl analogue of MDA and the N-methyl derivative of MDMA. The drug is a known synthetic impurity of MDMA and has also been described as a possible novel designer drug in 2025. In addition, (R)-MDDMA was characterized as a non-hallucinogenic psychoplastogen with antidepressant-like effects and improved safety relative to MDMA in 2026.
Neanderthals also consumed a variety of plants and mushrooms across their range — at Kebara Cave, Israel, over 50 species of seeds, nuts, fruits, and cereals. Neanderthals possibly employed a wide range of food preparation techniques. At Cueva del Sidrón, Spain, Neanderthals may have been roasting and smoking meat, and used certain plants—such as yarrow and camomile—for flavouring, although these plants may have instead been used for their medicinal properties. At Gorham's Cave, Gibraltar, Neanderthals may have been roasting pinecones to access pine nuts, and at Gruta da Figueira Brava, brown crabs to soften the shell before cracking them open. At Grotte du Lazaret, France, a total of twenty-three red deer, six ibexes, three aurochs, and one roe deer appear to have been hunted in a single autumn hunting season, when strong male and female deer herds would group together for rut. It is possible these Neanderthals were curing and storing all this meat before winter set in. Neanderthals at Neumark-Nord may have been rendering fat from animal bones to offset protein toxicity. Likewise, calcium measurements suggest that Neanderthals at Grotte du Bison frequently consumed bone. Neanderthals competed with several large carnivores, but also seem to have hunted them down, namely cave lions and wolves, as well as cave and brown bear both in and out of hibernation. Neanderthals and other predators may have sometimes avoided competition by pursuing different prey, namely with cave hyenas and wolves (niche differentiation).
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.